Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has made a 30.74% comeback from a 12-month low price of $11.45. It was seen 7.01% higher, changing the price to $14.97, when the closing bell rang on 01/11/2019. At recent session, the prices were hovering between $13.8 and $15.06. This company shares are 176.55% off its target price of $41.4 and the current market capitalization stands at $786.82M. The recent change has given its price a -1.56% deficit over SMA 50 and -53.22% deficit over its 52-week high. The stock witnessed -16.56% declines, -0.93% declines and -20.37% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found APLS’s volatility during a week at 7.01% and during a month it has been found around 8.94%.Apellis Pharmaceuticals, Inc. (APLS) Top Holders
Institutional investors currently hold around $472 million or 57.9% in APLS stock. Look at its top three institutional owners. Hillhouse Capital Management, Ltd. owns $64.79 million in Apellis Pharmaceuticals, Inc., which represents roughly 8.23% of the company’s market cap and approximately 13.73% of the institutional ownership. Similar statistics are true for the second largest owner, Cormorant Asset Management, Lp, which owns 4,172,498 shares of the stock are valued at $62.46 million. The third largest holder is Blackrock Inc., which currently holds $42.71 million worth of this stock and that ownership represents nearly 5.43% of its market capitalization.
At the end of September reporting period, 46 institutional holders increased their position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by some 2,313,537 shares, 28 decreased positions by 3,140,105 and 12 held positions by 26,066,276. That puts total institutional holdings at 31,519,918 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 162,405 shares while 6 institutional investors sold out their entire positions totaling 225,850 shares.Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Trades
Multiple company employees have indulged in significant insider trading. Apellis Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Morningside Venture Investment has acquired 81,323 shares of Apellis Pharmaceuticals, Inc. (APLS) in trading session dated Sep. 21, 2018. These shares are worth $1,584,172 and were traded at $19.48 each. The SEC filing shows that Morningside Venture Investment performed a purchase of 140,000 shares. The 10% Owner added these shares by way of transaction on Sep. 19, 2018. The company’s shares were assimilated at $18.34 per share worth to an investment of some $2,567,600 on account of Morningside Venture Investment.
General Counsel, Watson David O., sold 15,776 common shares of Apellis Pharmaceuticals, Inc. (APLS) in the open market. In a transaction dated Sep. 14, 2018, the shares were put up for sale at an average price of $18.78, raking in a sum of $296,273. After this sale, 27,042 common shares of APLS are directly owned by the insider, with total stake valued at $404,819.
In the transaction dated May. 24, 2018, the great number of shares acquired came courtesy the; Scheibler Lukas added a total of 2,935 shares at an average price of $20.37, amounting to approximately $59,786. The insider now directly owns 2,935 shares worth $43,937.
Several analysts have released their opinion on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation.